<DOC>
	<DOCNO>NCT01231230</DOCNO>
	<brief_summary>The addition inhale long-acting beta-adrenergic agonist inhale glucocorticosteroid improves disease control persistent asthma . This observation support use long-acting beta-adrenergic agonist/glucocorticosteroid combination preparation management asthma . Currently , salmeterol/fluticasone formoterol/budesonide available clinical use . The long-term beneficial clinical effect two drug class seem synergistic , several mechanism glucocorticoid-beta-adrenergic agonist interaction involve gene transcription invoke explain phenomenon.This study , wish address question whether glucocorticoid acutely potentiate bronchodilator response long-acting beta-adrenergic agonist.We expect patient asthma , short-term bronchodilator effect salmeterol enhance addition fluticasone , short-term bronchodilator effect . To test premise , assess respective short-term effect salmeterol ( 50 µg ) , fluticasone ( 250 µg ) , salmeterol/fluticasone ( 50/250 µg ) , placebo/placebo spirometric parameter . Airway Blood flow also measure ensure vasoconstriction occur .</brief_summary>
	<brief_title>Interactive Acute Smooth Muscle Effects Salmeterol Fluticasone Airway</brief_title>
	<detailed_description>Fourteen lifetime nonsmoker physician diagnosis asthma recruit study . All subject allow use short-acting beta-adrenergic agonist rescue medication . Inclusion criterion : 1 . Males female , 18 65 year age . 2 . FEV1 60-85 % predict screening day . Exclusion criterion : 1 . Women childbearing potential use accept birth control measure ; pregnant breast feed woman . 2 . Cardiovascular disease and/or use cardiovascular medication 2 . Subjects know beta-adrenergic agonist glucocorticosteroid intolerance 4 . Acute respiratory infection within four week prior study 5 . Use , within two week prior study , anti-asthma medication mention</detailed_description>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<criteria>1 . Males female , 18 65 year age . 2 . FEV1 6085 % predict screening day . 1 . Women childbearing potential use accept birth control measure ; pregnant breast feed woman . 2 . Cardiovascular disease and/or use cardiovascular medication 3 . Subjects know betaadrenergic agonist glucocorticosteroid intolerance 4 . Acute respiratory infection within four week prior study 5 . Use , within two week prior study , antiasthma medication mention</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>asthma , corticosteroid , bronchodilator , airway blood flow</keyword>
</DOC>